EKF Diagnostics, the point of care diagnostics company, announced that Interim results to June 2011 (with pro-forma comparative results) showed sales of £7.4 million (2010: £6.0 million) and adjusted EBITDA of £210,000 (2010: £(51,000)). The pre-tax loss was £1.55 million (2010: £(302,000)), actual not pro-forma.
The company reported that the period was impacted by the costs involved in moving from an essentially owner-managed structure and culture to one that is more reflective of the demands of a higher-growth/higher governance led environment. Gross margin was 64% (2010: 58%). Period end net cash was £2.8 million.
The EKF share price has increased by 3% over the past year.
EKF Diagnostic Holdings Plc is currently graded C by LCF Research. To learn more, follow the link.
